140 related articles for article (PubMed ID: 35632669)
1. Inflammatory Markers after Switching to a Dual Drug Regimen in HIV-Infected Subjects: A Two-Year Follow-Up.
Vassallo M; Durant J; Fabre R; Lotte L; Sindt A; Puchois A; De Monte A; Cezar R; Corbeau P; Pradier C
Viruses; 2022 Apr; 14(5):. PubMed ID: 35632669
[TBL] [Abstract][Full Text] [Related]
2. Switching to a Dual-Drug Regimen in HIV-Infected Patients Could Be Associated With Macrophage Activation?
Vassallo M; Durant J; Fabre R; Ticchioni M; Lotte L; Sindt A; Puchois A; De Monte A; Cezar R; Corbeau P; Pradier C
Front Med (Lausanne); 2021; 8():712880. PubMed ID: 34458287
[No Abstract] [Full Text] [Related]
3. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
[TBL] [Abstract][Full Text] [Related]
4. Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study.
Hattab S; Guihot A; Guiguet M; Fourati S; Carcelain G; Caby F; Marcelin AG; Autran B; Costagliola D; Katlama C
BMC Infect Dis; 2014 Mar; 14():122. PubMed ID: 24589015
[TBL] [Abstract][Full Text] [Related]
5. Maintenance of virologic efficacy and decrease in levels of β2-microglobulin, soluble CD40L and soluble CD14 after switching previously treated HIV-infected patients to an NRTI-sparing dual therapy.
Romero-Sánchez MC; Alvarez-Ríos AI; Bernal-Morell E; Genebat M; Vera F; Benhnia MR; Bravo-Urbieta J; Galera-Peñaranda C; de Pablo-Bernal RS; Abad-Carrillo MA; Leal M; Ruiz-Mateos E;
Antiviral Res; 2014 Nov; 111():26-32. PubMed ID: 25173576
[TBL] [Abstract][Full Text] [Related]
6. Switching to dual antiretroviral regimens is associated with improvement or no changes in activation and inflammation markers in virologically suppressed HIV-1-infected patients: the TRILOBITHE pilot study.
Vallejo A; Molano M; Monsalvo-Hernando M; Hernández-Walias F; Fontecha-Ortega M; Casado JL
HIV Med; 2019 Sep; 20(8):555-560. PubMed ID: 31131528
[TBL] [Abstract][Full Text] [Related]
7. Influence of episodes of intermittent viremia ("blips") on immune responses and viral load rebound in successfully treated HIV-infected patients.
Castro P; Plana M; González R; López A; Vilella A; Nicolas JM; Gallart T; Pumarola T; Bayas JM; Gatell JM; García F
AIDS Res Hum Retroviruses; 2013 Jan; 29(1):68-76. PubMed ID: 23121249
[TBL] [Abstract][Full Text] [Related]
8. Soluble biomarkers of immune activation and inflammation in HIV infection: impact of 2 years of effective first-line combination antiretroviral therapy.
Hattab S; Guiguet M; Carcelain G; Fourati S; Guihot A; Autran B; Caby F; Marcelin AG; Costagliola D; Katlama C
HIV Med; 2015 Oct; 16(9):553-62. PubMed ID: 25944318
[TBL] [Abstract][Full Text] [Related]
9. NRTI Sparing Therapy in Virologically Controlled HIV-1 Infected Subjects: Results of a Controlled, Randomized Trial (Probe).
Maggiolo F; Di Filippo E; Valenti D; Serna Ortega PA; Callegaro A
J Acquir Immune Defic Syndr; 2016 May; 72(1):46-51. PubMed ID: 26910503
[TBL] [Abstract][Full Text] [Related]
10. Dual nucleoside reverse transcriptase inhibitor therapy in the combination antiretroviral therapy era and predictors of discontinuation or switch to combination antiretroviral therapy.
Selinger-Leneman H; Matheron S; Mahamat A; Moreau J; Costagliola D; Abgrall S;
J Acquir Immune Defic Syndr; 2008 Feb; 47(2):206-11. PubMed ID: 17971717
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of viremia and microbial translocation on immune activation in HIV-infected patients throughout ritonavir-boosted darunavir monotherapy.
BenMarzouk-Hidalgo OJ; Torres-Cornejo A; Gutiérrez-Valencia A; Ruiz-Valderas R; Viciana P; López-Cortés LF
Medicine (Baltimore); 2015 May; 94(17):e781. PubMed ID: 25929922
[TBL] [Abstract][Full Text] [Related]
12. Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.
Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
AIDS; 2006 Oct; 20(16):2099-106. PubMed ID: 17053356
[TBL] [Abstract][Full Text] [Related]
13. Reduction of inflammation and T cell activation after 6 months of cART initiation during acute, but not in early chronic HIV-1 infection.
de Paula HHS; Ferreira ACG; Caetano DG; Delatorre E; Teixeira SLM; Coelho LE; João EG; de Andrade MM; Cardoso SW; Grinsztejn B; Veloso VG; Morgado MG; Guimarães ML; Côrtes FH
Retrovirology; 2018 Dec; 15(1):76. PubMed ID: 30541557
[TBL] [Abstract][Full Text] [Related]
14. Protease inhibitor monotherapy is associated with a higher level of monocyte activation, bacterial translocation and inflammation.
Torres B; Guardo AC; Leal L; Leon A; Lucero C; Alvarez-Martinez MJ; Martinez MJ; Vila J; Martínez-Rebollar M; González-Cordón A; Gatell JM; Plana M; García F
J Int AIDS Soc; 2014; 17(1):19246. PubMed ID: 25280865
[TBL] [Abstract][Full Text] [Related]
15. Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial.
Bussmann H; Wester CW; Thomas A; Novitsky V; Okezie R; Muzenda T; Gaolathe T; Ndwapi N; Mawoko N; Widenfelt E; Moyo S; Musonda R; Mine M; Makhema J; Moffat H; Essex M; Degruttola V; Marlink RG
J Acquir Immune Defic Syndr; 2009 May; 51(1):37-46. PubMed ID: 19282782
[TBL] [Abstract][Full Text] [Related]
16. Is low-level HIV-1 viraemia associated with elevated levels of markers of immune activation, coagulation and cardiovascular disease?
Elvstam O; Medstrand P; Jansson M; Isberg PE; Gisslén M; Björkman P
HIV Med; 2019 Oct; 20(9):571-580. PubMed ID: 31148335
[TBL] [Abstract][Full Text] [Related]
17. A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.
García F; Romeu J; Grau I; Sambeat MA; Dalmau D; Knobel H; Gomez-Sirvent JL; Arrizabalaga J; Cruceta A; Clotet BG; Podzamczer D; Pumarola T; Gallart T; O'Brien WA; Miró JM; Gatell JM
AIDS; 1999 Dec; 13(17):2377-88. PubMed ID: 10597779
[TBL] [Abstract][Full Text] [Related]
18. Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: a multicenter retrospective cohort study from 2007 to 2015.
Quiros-Roldan E; Magro P; Raffetti E; Izzo I; Borghetti A; Lombardi F; Saracino A; Maggiolo F; Castelli F;
BMC Infect Dis; 2018 Jun; 18(1):285. PubMed ID: 29940869
[TBL] [Abstract][Full Text] [Related]
19. A plasma biomarker signature of immune activation in HIV patients on antiretroviral therapy.
Kamat A; Misra V; Cassol E; Ancuta P; Yan Z; Li C; Morgello S; Gabuzda D
PLoS One; 2012; 7(2):e30881. PubMed ID: 22363505
[TBL] [Abstract][Full Text] [Related]
20. Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002.
Lampe FC; Gatell JM; Staszewski S; Johnson MA; Pradier C; Gill MJ; de Lazzari E; Dauer B; Youle M; Fontas E; Krentz HB; Phillips AN
Arch Intern Med; 2006 Mar; 166(5):521-8. PubMed ID: 16534038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
